Literature DB >> 8935799

Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.

A M Deveney1, J L Waddington.   

Abstract

The effects of the putative atypical antipsychotics olanzapine and ICI 204,636 on behavioural responses to the selective "D2-like" dopamine receptor agonist RU 24213 and to the selective "D1-like" agonist A 68930 were compared with those of the prototype atypical antipsychotic clozapine, the selective D1-like antagonist SCH 23390 and the selective D2-like antagonist YM 09151-2. Olanzapine (0.4-2.0 mg/kg) and ICI 204,636 (4.0-36.0 mg/kg), like clozapine (4.0-36.0 mg/kg) and SCH 23390 (0.01-1.0 mg/kg), effected at best modest reduction in typical sniffing and locomotor responses and, with the exception of ICI 204,636, released episodes of atypical myoclonic jerking to RU 24213 (12.5 mg/kg); a high dose of olanzapine (10.0 mg/kg), like YM 09151-2 (0.005-0.5 mg/kg), blocked all responsivity to RU 24213. Conversely, olanzapine (0.4-2.0 mg/kg) and ICI 204,636 (4.0-36.0 mg/kg), like clozapine (4.0-12.0 mg/kg) and SCH 23390 (0.01-0.1 mg/kg), readily blocked typical grooming responses to A 68930 (0.5 mg/kg); YM 09151-2 failed to block grooming and exerted more variable effects. Olanzapine and, to a lesser extent, ICI 204,636 share with clozapine a preferential action to attenuate D1-mediated function; given their lack of selective affinity for D1-like receptors, this common effect may be exerted at an alternative level of synaptic function. The action of olanzapine and particularly ICI 204,636 to release additional episodes of atypical vacuous chewing to A 68930 indicates some deviation from a wholly clozapine-like profile, the clinical significance of which remains to be specified.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935799     DOI: 10.1007/bf02245604

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  39 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.

Authors:  A Y Deutch; B Moghaddam; R B Innis; J H Krystal; G K Aghajanian; B S Bunney; D S Charney
Journal:  Schizophr Res       Date:  1991 Mar-Apr       Impact factor: 4.939

2.  Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase.

Authors:  A M Deveney; J L Waddington
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

3.  Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine 'D1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase.

Authors:  R P Downes; J L Waddington
Journal:  Eur J Pharmacol       Date:  1993-03-30       Impact factor: 4.432

4.  Induction of oral dyskinesias in naive rats by D1 stimulation.

Authors:  H Rosengarten; J W Schweitzer; A J Friedhoff
Journal:  Life Sci       Date:  1983-12-19       Impact factor: 5.037

5.  Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390.

Authors:  A G Molloy; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels.

Authors:  C Euvrard; L Ferland; T Di Paolo; M Beaulieu; F Labrie; C Oberlander; J P Raynaud; J R Boissier
Journal:  Neuropharmacology       Date:  1980-04       Impact factor: 5.250

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 8.  Dopamine receptor subtypes: beyond the D1/D2 classification.

Authors:  P H Andersen; J A Gingrich; M D Bates; A Dearry; P Falardeau; S E Senogles; M G Caron
Journal:  Trends Pharmacol Sci       Date:  1990-06       Impact factor: 14.819

9.  The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioural indices.

Authors:  A M Murray; J L Waddington
Journal:  Eur J Pharmacol       Date:  1990-09-04       Impact factor: 4.432

10.  Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

View more
  2 in total

Review 1.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.

Authors:  B Fulton; K L Goa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.